Understanding m6A changes in chromophobe renal cell carcinoma and predicting patient outcomes survival.

N6-methyladenosine (mA) is a prevalent mRNA modification known for its implications in various cancer types, yet its role in chromophobe renal cell carcinoma (chRCC) remains largely unexplored. In this study, we performed m6A-SEAL-seq and RNA-seq analyses on tissues from three chRCC subjects, aiming to uncover mA alterations in chRCC. Our findings revealed reduced expression levels of four mA regulators in chRCC tissues and highlighted differences in mA levels compared to normal tissues. Furthermore, we identified specific genes and cancer-related pathways affected by these differences, including notable candidates like NOTCH1 and FGFR1, implicated in chRCC development. Additionally, we developed a predictive model based on the expression level of mA associated genes, demonstrating promising prognostic capabilities for patient survival prediction. Overall, our study provides valuable insights into the role of mA in chRCC and its potential as a prognostic indicator.